Introduction

Mild‑to‑moderate allergic asthma is asthma in which airway inflammation and symptoms are triggered by sensitization to environmental allergens (e.g., house dust mites, grass or ragweed pollen, pet dander). For the right patients, sublingual immunotherapy (SLIT) tablets can reduce exacerbations and medication needs while improving control—always as an add‑on to guideline‑directed asthma therapy, not a replacement.

• This page explains when SLIT helps, strict eligibility criteria, safety requirements (first‑dose supervision and epinephrine), and how Wyndly coordinates SLIT with a patient’s asthma action plan.

• FDA‑approved SLIT tablets in the United States exist for house dust mite (HDM), Timothy grass, a 5‑grass mix, and ragweed. These products are approved for allergic rhinitis/conjunctivitis; using them to improve asthma outcomes is off‑label in the U.S. and should follow guideline criteria and shared decision‑making.

References throughout link to FDA labeling, randomized trials, and major guidelines (GINA, AAAAI/ACAAI).

What allergic asthma is—and why SLIT can help

Allergic asthma is driven by IgE‑mediated sensitization to inhalant allergens. On exposure, downstream inflammation narrows airways and worsens cough, wheeze, and shortness of breath. SLIT delivers daily, precisely standardized allergen doses under the tongue to induce immune tolerance over time, decreasing reactivity to that allergen. FDA‑approved tablets exist for:

• House dust mite (HDM): Odactra (12 SQ‑HDM)

• Timothy grass: Grastek (2800 BAU)

• 5‑grass mix: Oralair (300 IR)

• Short ragweed: Ragwitek (12 Amb a 1‑U)

Labels, dosing, and boxed warnings (e.g., need for first‑dose observation and epinephrine) are available in FDA‑derived resources and manufacturer medication guides (e.g., Odactra, Grastek, Oralair, Ragwitek).

Key evidence for asthma:

• HDM tablet SLIT lowered risk of asthma exacerbations and reduced inhaled corticosteroid (ICS) use in randomized trials of HDM‑sensitized adults with asthma. See the JAMA randomized clinical trial of the SQ‑HDM tablet demonstrating improved control and reduced future risk.

• Global Initiative for Asthma (GINA) allows HDM SLIT as an add‑on for adolescents/adults with HDM sensitization and persisting symptoms despite low‑to‑medium dose ICS, provided FEV1 criteria are met and asthma is not severe or unstable. GINA also notes seasonal SLIT options (e.g., ragweed) in selected pediatric cases with adequate lung function.

Selected sources: JAMA HDM‑SLIT RCT; GINA 2024 update summary; AAAAI/ACAAI patient education on SLIT indications and limitations; FDA/labeling for first‑dose supervision and epinephrine.

Who is an appropriate SLIT candidate (table applies to tablets in the U.S.)

Use SLIT only after confirming sensitization to the exact allergen contained in the tablet and ensuring the patient can dose daily. All decisions should be individualized and made jointly with the treating asthma clinician.

Requirement	Rationale / details
Confirmed IgE sensitization to the target allergen	Positive skin‑prick or specific IgE (e.g., Dermatophagoides farinae/pteronyssinus for Odactra; Timothy/5‑grass for Grastek/Oralair; short ragweed for Ragwitek). Payer criteria commonly require documented sensitization.
Mild‑to‑moderate allergic asthma with comorbid allergic rhinitis to the target allergen	Evidence for asthma benefit is strongest for HDM SLIT in HDM‑sensitized asthma; pollen tablets primarily carry rhinitis indications in the U.S.
Asthma controlled or partially controlled on guideline therapy	Per GINA, consider HDM SLIT when symptoms persist despite low‑to‑medium dose ICS, with FEV1 typically >70% predicted and no recent severe exacerbation.
Ability to adhere to daily dosing for years	SLIT modifies disease only with consistent daily dosing across seasons/years.
First dose administered under medical supervision	Required by FDA labeling with ≥30‑minute post‑dose observation.
Epinephrine auto‑injector prescribed and patient trained	Mandatory per tablet labeling for home dosing.

Clinical references: GINA 2024; Odactra, Grastek, Oralair, Ragwitek labeling/medication guides; AAAAI/ACAAI summaries.

Who should NOT start SLIT tablets

Absolute or label‑level contraindications include:

• Severe, unstable, or uncontrolled asthma (do not initiate; stabilize first).

• Prior severe systemic reaction to any immunotherapy or severe local reaction to SLIT.

• History of eosinophilic esophagitis (EoE) or current EoE symptoms (dysphagia, chest pain).

• Hypersensitivity to tablet excipients.

• Inability to use epinephrine or conditions/medications that make epinephrine ineffective (e.g., some beta‑blockers) without risk mitigation.

These exclusions are stated across FDA medication guides and prescribing information and echoed by professional society materials.

Safety and administration checklist

• First dose in clinic with observation: The initial tablet must be taken under supervision with ≥30‑minute monitoring for anaphylaxis or severe local reactions. Thereafter, dosing is at home once daily (labels for Odactra/Grastek/Oralair/Ragwitek).

• Epinephrine: Co‑prescribe an auto‑injector; teach recognition of severe reactions and immediate use, then seek emergency care; pause SLIT and contact the prescriber after any severe reaction.

• Asthma stability: Withhold SLIT during any acute asthma exacerbation; reassess control before resuming.

• Common adverse effects: Oral pruritus, throat irritation, mild edema; typically diminish with continued use. EoE is rare but requires permanent discontinuation if suspected (per labels).

• Comparative safety: Large safety reviews report a markedly lower anaphylaxis risk with SLIT than with injections; nonetheless, tablet SLIT carries a boxed warning, and precautions must be followed.

Primary sources: FDA labeling/medication guides; safety reviews from AAAAI/ACAAI surveillance; Mayo Clinic/Odactra patient instructions.

How SLIT fits into an asthma action plan

SLIT is an add‑on that targets the allergic driver; it does not replace controller medicines.

• Maintain guideline therapy: Continue ICS (with or without LABA) and reliever per your current plan; adjust pharmacotherapy per objective control.

• Baseline before starting: Record recent exacerbations, ACT/ACQ score, rescue use, and spirometry (FEV1)—and ensure FEV1 meets guideline thresholds (commonly >70% predicted for HDM SLIT; some pediatric seasonal use requires ≥80%).

• Written plan: Update the asthma action plan with clear instructions on when to step‑up inhaled therapy and when to hold SLIT (e.g., during an exacerbation) and how to use epinephrine for systemic reactions.

• Monitoring: Reassess symptoms, reliever use, and lung function periodically (e.g., every 3–6 months). Consider de‑escalation of ICS only after sustained control and shared decision‑making.

Guidance: GINA 2024 framework for HDM SLIT add‑on and stability criteria.

Which SLIT tablets exist in the U.S. (and typical use)

• House dust mite (Odactra; ages 12–65): daily year‑round for HDM‑driven rhinitis; add‑on for HDM‑sensitized asthma may be considered under GINA criteria (off‑label for asthma outcomes in the U.S.).

• Timothy grass (Grastek; ages 5–65) and 5‑grass (Oralair; ages 5–65): seasonal pre‑/co‑seasonal dosing for grass‑pollen rhinitis; limited, mostly rhinitis‑focused indications; asthma benefits are secondary and patient‑specific.

• Short ragweed (Ragwitek; ages 5–65): seasonal pre‑/co‑seasonal dosing for ragweed rhinitis; GINA notes selected pediatric use with adequate lung function during ragweed season.

Always follow label‑mandated first‑dose supervision and epinephrine training for any tablet.

Authoritative sources: FDA/Drugs.com prescribing information and manufacturer medication guides (Odactra, Grastek, Oralair, Ragwitek) and GINA 2024 summary.

Wyndly’s role (doctor‑led, tablet‑first when appropriate)

Wyndly treats environmental (not food) allergies and can coordinate SLIT with your asthma care team:

• Confirm the allergic driver with a CLIA‑certified, at‑home specific‑IgE test and a physician review of your history and spirometry trends.

• If you’re an appropriate candidate, our physicians can prescribe an FDA‑approved tablet (e.g., HDM, grass, ragweed) and arrange the required first supervised dose and epinephrine prescription; subsequent dosing is at home with 24/7 access to our team.

• We do not start SLIT in uncontrolled or severe asthma and will defer to your asthma clinician for stabilization. We do not treat food allergy.

Learn more: our overview of Immunotherapy at Wyndly and an explainer on what SLIT is (and U.S. FDA approval for tablets vs off‑label uses).

Practical eligibility quick‑list

Use this as a concise pre‑visit screen:

• Documented sensitization to HDM/grass/ragweed matching a tablet product.

• Mild‑to‑moderate allergic asthma with comorbid allergic rhinitis to that allergen.

• FEV1 meets guideline thresholds (commonly >70% predicted for HDM SLIT) and no severe exacerbation in the past 3 months.

• Daily dosing feasible for years; agrees to first‑dose supervision and to carry/use epinephrine.

• No exclusion listed above (uncontrolled asthma, EoE, prior severe immunotherapy reaction, etc.).

Key sources

• GINA 2024 update—SLIT positioning, lung‑function thresholds, and add‑on criteria: Clinical Advisor summary of GINA 2024 recommendations.

• HDM SLIT efficacy in asthma: JAMA randomized clinical trial of SQ‑HDM tablet (reduced exacerbations, steroid‑sparing).

• Tablet safety/label requirements (first‑dose supervision, epinephrine, contraindications including uncontrolled asthma and EoE): Odactra; Grastek; Oralair; Ragwitek.

• Professional society patient guidance on approved SLIT uses and contraindications: AAAAI/ACAAI patient education summary.

Disclosures and scope

• United States context as of November 12, 2025. Tablet indications in the U.S. are for allergic rhinitis/conjunctivitis; asthma improvement is an off‑label outcome and is considered only for carefully selected patients under guideline criteria. Wyndly treats environmental allergies; we do not treat food allergies.